GLP-1 Receptor Agonist Drugs Market (2026-2032)

GLP-1 Receptor Agonist Drugs Market: Obesity Treatment, Cardiometabolic Protection and Oral Therapy Expand a USD 40 Billion Drug Class

The Global GLP-1 Receptor Agonist Drugs Market was valued at approximately USD 40.1 billion in 2025 and is projected to reach about USD 88.6 billion by 2032, expanding at a CAGR of approximately 12.0% during 2026–2032. Global treatment volume is estimated at approximately 10–13 million annual treated-patient equivalents in 2025. North America accounted for an estimated USD 26.1 billion, or about 65% of global revenue, with approximately 4.5–5.3 million annual treated-patient equivalents. The United States contributed approximately USD 25.6 billion, representing nearly 64% of global revenue, with an estimated 4.3–5.1 million annual treated-patient equivalents.

Novo Nordisk generated DKK 152.2 billion from GLP-1 therapies for type 2 diabetes and DKK 82.35 billion from obesity-care products in 2025. At the company's reported average 2025 exchange rate of DKK 6.62 per U.S. dollar, these businesses represented approximately USD 35.4 billion. Eli Lilly generated another USD 4.28 billion from Trulicity, including USD 2.91 billion in the United States. Together, these products accounted for approximately USD 39.7 billion before smaller contributions from exenatide, lixisenatide, generic liraglutide and other regional products, supporting the estimated USD 40.1 billion global market base.

The market definition is intentionally narrower than forecasts for the broader incretin market. Tirzepatide is a dual GIP/GLP-1 receptor agonist and is not included in the core pure GLP-1 market calculation, although Mounjaro and Zepbound remain major competitive therapies. Morgan Stanley reported approximately USD 79 billion in 2025 sales across the wider GLP-1/incretin category and expects the broader diabetes and obesity treatment market to reach approximately USD 190 billion by 2035. UBS separately projected 40 million people receiving GLP-1 therapies by 2029 and USD 126 billion in sales. The difference between those broader forecasts and the USD 40.1 billion pure GLP-1 estimate largely reflects inclusion of tirzepatide and other multi-receptor therapies.

Diabetes and Obesity Create One of the Largest Eligible Patient Pools in Pharmaceutical Care

The clinical population supporting GLP-1 treatment is exceptionally large. According to the International Diabetes Federation, approximately 589 million adults aged 20–79 were living with diabetes in 2024, and diabetes-related global health expenditure reached approximately USD 1.015 trillion, equal to about 12% of global health expenditure. Average health expenditure reached approximately USD 1,760 per person with diabetes.

The treatment opportunity remains considerably larger than current GLP-1 penetration. Novo Nordisk reported that GLP-1 therapies represented only 8.1% of total global diabetes prescriptions in 2025, up from 6.7% a year earlier. The company generated DKK 127.09 billion from Ozempic, DKK 22.09 billion from Rybelsus and DKK 3.02 billion from Victoza during 2025. Ozempic alone therefore represented more than four-fifths of Novo Nordisk's GLP-1 diabetes revenue.

Obesity provides an even larger potential treatment population. According to the World Health Organization, more than 890 million adults were living with obesity in 2022, while approximately 2.5 billion adults were overweight. WHO also estimates that high BMI contributed to approximately 3.7 million deaths from noncommunicable diseases in 2021. Without stronger prevention and treatment, the global economic cost of overweight and obesity is projected to reach approximately USD 3 trillion annually by 2030 and exceed USD 18 trillion by 2060.

The World Obesity Federation projects the number of adults living with obesity to rise from 524 million in 2010 to approximately 1.13 billion by 2030. Despite this burden, Novo Nordisk estimates that only around 2% of people living with obesity currently receive medical treatment, leaving a substantial gap between disease prevalence and pharmacological management.

The United States Combines High Disease Burden With the Deepest Commercial Penetration

The United States remains the largest individual GLP-1 market. Novo Nordisk's 2025 U.S. sales included approximately DKK 88.47 billion from Ozempic, DKK 8.83 billion from Rybelsus, DKK 471 million from Victoza, DKK 51.02 billion from Wegovy and DKK 268 million from Saxenda. These products generated approximately DKK 149.1 billion, equivalent to about USD 22.5 billion using Novo Nordisk's reported 2025 average exchange rate. Adding Lilly's USD 2.91 billion in U.S. Trulicity sales and smaller products supports an estimated USD 25.6 billion U.S. pure GLP-1 market in 2025.

North America is estimated at approximately USD 26.1 billion, with Canada accounting for a relatively small additional contribution beyond the United States. The region therefore represented approximately 65% of global pure GLP-1 revenue in 2025. Revenue concentration substantially exceeds North America's share of the global diabetes and obesity population because of higher realized drug prices, greater branded-drug penetration, broader commercial insurance coverage and faster adoption of pharmacological obesity treatment.

The U.S. patient pool remains significant, supported by the high prevalence of obesity and related metabolic conditions. According to the CDC's January 2026 National Diabetes Statistics Report, 40.1 million Americans had diagnosed or undiagnosed diabetes in 2023, including 29.1 million diagnosed patients and approximately 11.0 million undiagnosed adults. Another 115.2 million U.S. adults had prediabetes, creating a large population at risk of progressing into the diabetes treatment pool.

The large number of people living with obesity in the United States creates a substantial potential treatment population for these therapies. The latest CDC/NCHS data show that 40.3% of U.S. adults aged 20 years and older had obesity during August 2021–August 2023, while 72.4% had overweight including obesity. Severe obesity affected approximately 9.7% of adults on an age-adjusted basis.

GLP-1 penetration is already material among patients with diabetes. According to the CDC, 26.5% of U.S. adults with diagnosed diabetes reported using an injectable GLP-1 drug in 2024, rising to 33.3% among adults aged 50–64. Utilization was also higher among adults with greater BMI, showing the strong overlap between diabetes and obesity treatment populations.

Population surveys show that GLP-1 and other incretin-based therapies are being used by a growing share of patients. A KFF survey conducted in late 2025 found that 18% of U.S. adults had ever used a GLP-1 medication and 12% reported currently using one, compared with 6% current use in 2024. Among adults reporting a diabetes diagnosis, 45% said they were currently using a GLP-1 medication; among those told they had overweight or obesity, 23% reported current use. These survey figures include dual agonists such as tirzepatide and therefore should not be interpreted as pure GLP-1 treatment volume, but they demonstrate how quickly incretin therapy has entered routine U.S. care.

Diabetes Complications Strengthen the Value of Long-Term GLP-1 Treatment

The economic burden of diabetes gives cardiovascular and renal outcome benefits increasing importance in treatment decisions. According to an American Diabetes Association analysis published in Diabetes Care, diagnosed diabetes generated approximately USD 412.9 billion in U.S. economic costs in 2022, including USD 306.6 billion in direct medical costs and USD 106.3 billion in indirect costs. People with diagnosed diabetes incurred average annual medical expenditure of approximately USD 19,736, of which USD 12,022 was attributable to diabetes, and medical spending was approximately 2.6 times higher than expected for people without diabetes.

These costs extend well beyond glucose-lowering medication. Cardiovascular disease, chronic kidney disease, hospitalizations and other diabetes-related complications contribute materially to lifetime expenditure. This supports greater clinical value for GLP-1 therapies that demonstrate benefits across glycemic control, body weight and major organ outcomes rather than HbA1c reduction alone.

Ozempic received an expanded U.S. indication in January 2025 to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and CKD. The approval followed the FLOW trial and expanded semaglutide into a high-risk population requiring long-term renal and cardiovascular management.

Obesity Is Moving From an Under-Treated Condition to a Major Pharmaceutical Application

The obesity application has changed the scale of the GLP-1 market. Novo Nordisk reported that the global branded GLP-1 obesity market increased 104% by volume during 2025, while its obesity-care revenue reached DKK 82.35 billion. Wegovy accounted for DKK 79.11 billion of this total, compared with DKK 3.24 billion for Saxenda.

The U.S. accounted for the majority of this revenue. Wegovy generated DKK 51.02 billion in U.S. sales during 2025, and Novo Nordisk reported approximately 230,000 weekly U.S. Wegovy prescriptions by January 23, 2026. Around 70,000 weekly prescriptions were flowing through the company's retail self-pay NovoCare channel, indicating that cash-pay and direct-to-patient channels have become meaningful alongside conventional insurance reimbursement.

The broader health burden remains substantial. CDC estimates that obesity accounts for approximately USD 173 billion in annual U.S. medical expenditure in 2019 dollars, while adults with obesity incur around USD 1,861 more in annual medical expenditure than adults with healthy weight. Approximately 23% of U.S. adults with obesity also have diabetes, reinforcing the overlap between the two major GLP-1 treatment populations.

Cardiovascular, Kidney and Liver Indications Are Broadening Semaglutide Beyond Weight and Glycemic Control

Semaglutide's approved uses increasingly cover multiple components of cardiometabolic disease. In March 2024, the FDA approved Wegovy to reduce cardiovascular death, myocardial infarction and stroke in adults with established cardiovascular disease and overweight or obesity. In the supporting SELECT trial involving more than 17,600 participants, major cardiovascular events occurred in 6.5% of Wegovy-treated participants versus 8.0% receiving placebo, representing approximately a 20% relative risk reduction.

A further expansion occurred in August 2025 when the FDA approved Wegovy for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced F2–F3 fibrosis. FDA estimates indicate that approximately 14.9 million U.S. adults, or about 6% of adults, have MASH. In the ongoing Phase III study supporting accelerated approval, 63% of patients receiving Wegovy achieved MASH resolution without worsening fibrosis compared with 34% receiving placebo, while 37% achieved fibrosis improvement without worsening MASH compared with 22% on placebo.

These indications widen the clinically relevant population beyond diabetes and weight management into cardiovascular-risk reduction, diabetic kidney disease and progressive metabolic liver disease.

Pure GLP-1 Competition Is Concentrated Around Semaglutide, While Older Molecules Continue to Lose Share

Semaglutide dominates pure GLP-1 revenue through Ozempic, Wegovy and Rybelsus. Dulaglutide remains commercially important but is declining as newer therapies gain share. Lilly reported USD 4.28 billion in global Trulicity revenue in 2025, down from prior-year levels, including USD 2.91 billion in the United States and USD 1.36 billion outside the United States.

Liraglutide has also moved into a mature stage of its lifecycle. Novo Nordisk reported DKK 3.02 billion in Victoza sales and DKK 3.24 billion in Saxenda sales during 2025. The company specifically attributed the decline in Victoza partly to movement of the diabetes market toward once-weekly GLP-1 therapies.

The pure GLP-1 category now includes injectable and oral semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide and newer oral therapy. Foundayo (orforglipron) moved out of the pipeline after receiving FDA approval on April 1, 2026 for long-term weight reduction in adults with obesity or overweight plus at least one weight-related comorbidity. Its approval adds a once-daily oral small-molecule GLP-1 receptor agonist and increases competition for patients who prefer to avoid injections.

Novo Nordisk also received FDA approval in March 2026 for Wegovy HD, semaglutide 7.2 mg, extending its obesity franchise with a higher-dose injectable option.

Multi-Receptor Drugs Are the Main Competitive Pressure on Pure GLP-1 Revenue

Tirzepatide should not be classified as a pure GLP-1 receptor agonist because it targets both GIP and GLP-1 receptors. It nevertheless represents the largest competitive pressure on the market. Lilly reported USD 22.97 billion in Mounjaro sales and USD 13.54 billion in Zepbound sales during 2025, giving tirzepatide combined revenue of approximately USD 36.5 billion.

This distinction explains much of the difference between the estimated USD 40.1 billion pure GLP-1 market and Morgan Stanley's approximately USD 79 billion 2025 broader GLP-1/incretin market. Morgan Stanley estimates that around 6% of the U.S. population with obesity or diabetes was being treated with GLP-1/incretin therapies in 2025 compared with about 2% internationally, leaving substantial treatment headroom even after recent prescription growth.

Pipeline competition is also moving beyond single-receptor GLP-1 therapy. CagriSema combines semaglutide with the amylin analogue cagrilintide, while retatrutide targets GIP, GLP-1 and glucagon receptors. These therapies sit outside the strict pure GLP-1 market but will compete for the same diabetes and obesity patients and influence future treatment penetration, pricing and clinical expectations.

McKinsey reported that 11 GLP-1 and related medicines were marketed for diabetes and weight management as of February 2025, with more than 40 additional therapies in development. The development landscape increasingly includes oral small molecules, combination therapies and multi-receptor agents rather than another generation of conventional injectable GLP-1 monotherapy.

Low Treatment Penetration Remains the Largest Long-Term Opportunity

The central opportunity in the GLP-1 market remains the gap between clinical eligibility and sustained treatment. McKinsey estimates that almost 100 million U.S. adults and approximately 900 million adults globally meet clinical obesity criteria, while Novo Nordisk reports that only about 2% of people living with obesity currently receive medical treatment.

Treatment persistence remains another important constraint. McKinsey notes that real-world evidence has shown substantial discontinuation during the first year and that patients can regain a meaningful proportion of lost weight after treatment ends. Long-term revenue therefore depends not only on patient initiation but also continued treatment, tolerability, affordability and reimbursement.

UBS's U.S. GLP-1 user survey provides a contrasting signal among established users: 79% of surveyed patients reported using therapy for more than one year, and fewer than 10% were paying entirely out of pocket. Cost was the most frequently cited reason among patients who had stopped therapy. These findings reinforce reimbursement and persistence as important determinants of durable treatment volume.

GLP-1 Therapy Is Expanding Into a Broader Cardiometabolic Drug Platform

The GLP-1 receptor agonist market is no longer defined only by diabetes treatment or weight reduction. The class now includes approved uses across type 2 diabetes, chronic weight management, cardiovascular-risk reduction, diabetic chronic kidney disease and MASH, while oral products are broadening administration options.

The USD 40.1 billion 2025 pure GLP-1 market remains significantly smaller than the population theoretically eligible for treatment. Global diabetes affects nearly 589 million adults, more than 890 million adults live with obesity, and only 8.1% of global diabetes prescriptions were represented by GLP-1 therapy in 2025. In the United States, where market penetration is considerably higher, pure GLP-1 drugs already generated approximately USD 25.6 billion in annual revenue.

The next phase of market expansion will depend on sustained conversion of diagnosed diabetes and obesity populations into long-term treated patients, wider cardiovascular, renal and hepatic use, greater oral treatment adoption and broader payer coverage. At the same time, rapid growth of tirzepatide and next-generation multi-receptor agents means that the pure GLP-1 category will compete for patient share within a much larger incretin market rather than expanding without substitution pressure.

The projected increase from USD 40.1 billion in 2025 to approximately USD 88.6 billion by 2032 therefore reflects continued expansion of pure GLP-1 treatment while allowing for increasing competition from dual and multi-agonist therapies. The strongest commercial opportunity remains in the substantial gap between the hundreds of millions of patients with diabetes or obesity and the comparatively small population receiving persistent pharmacological treatment.